Drug name: Invokana
Company: Johnson & Johnson
Use: Type 2 diabetes
Amount spent on doctor payments: $7.16 million

Johnson & Johnson ($JNJ) scored first-in-class status with Invokana, the debut diabetes treatment in the SGLT-2 category. Approved in April 2013, the drug faced a twin challenge: One, compete with a host of other Type 2 diabetes treatments, including blockbusters such as Merck's ($MRK) Januvia and Novo Nordisk's ($NVO) Victoza. Two, build demand for a brand-new type of treatment, preferably before other SGLT-2 meds came on the scene to compete for share.

Novel treatment means doctor education, and that's exactly what J&J did. From August to December 2013, the company spent $7.16 million on payments to doctors for speaking fees and related spending, specifically to support Invokana, ProPublica notes. The company spent even more on advertising in academic journals in 2013: $16 million, according to Kantar Media statistics. -- Tracy Staton (email | Twitter)

For more:
Special Report: An ominous trend resurfaces as new drug approvals plunge in 2013 - Invokana: J&J advances a trailblazer in diabetes
FDA comes around on Boehringer, Lilly's diabetes med Jardiance
In SGLT2 diabetes fight, Lilly's empagliflozin loss is J&J and AstraZeneca's gain
J&J tops 2013 journal-ad ranks with millions in print support for Invokana, Xarelto
J&J faces big spending, big rivals for new diabetes drug Invokana


Suggested Articles

After showing Nucala could cut the rates of flares for hypereosinophilic syndrome, GSK is planning regulatory filings in 2020.

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Both IL-17A inhibitors have rolled out data showing they work in non-radiographic axial spondyloarthritis.